ACTION Consortium: $2 million for research

The ACTION Consortium launches its first research grant: $2 million. One of the largest ever in the field of neuroblastoma.

As you know, Nicole Scobie, President of Zoé4life, is actively involved in pediatric cancer research. In fact, she volunteers her time on an international level, to ensure that children are not forgotten by research.

To take concrete action, five non-profit organizations : Anticancer Fund, The Evan FoundationKindred FoundationSolving Kids' Cancer UK and Zoé4life have founded the ACTION Consortium. By pooling our resources, we will be able to allocate this $2 million grant to the project chosen by the consortium that meets the required criteria.

With the aim of bringing better treatment to children as quickly as possible, we want to drive and invest in clinical research, addressing the most unmet needs in childhood cancer.

To begin with, the Consortium has focused its first call for funding on one cancer: refractory and relapsed neuroblastoma. It calls for innovative approaches to accelerate clinical trials and the evaluation of new therapies.

ACTION - what is it and why?

It is a collective force committed to advancing the implementation and optimization of clinical trials in neuroblastoma. 

Our common goal is to challenge the scientific community!

How?

By asking the scientific community to put forward proposals likely to bring about significant changes in the neuroblastoma landscape.

Financing

The ACTION Consortium has developed and funded this call for projects. It is managed by Solving Kids' Cancer UK on behalf of the Consortium partners.

Applications

For all applications, please address your correspondence to: Leona Knox, research@resolutionkidscancer.org.uk.

Thanks to the resources pooled to form the ACTION Consortium, this grant will be awarded to the best project.

Our association is proud to support children with neuroblastoma through this Consortium.

Zoé4life financed this study to the tune of $ 200,000 in 2022.